These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 31445848)

  • 1. Incidence, risk factors and impact on virological response of anemia in chronic genotype 2 hepatitis C receiving sofosbuvir plus ribavirin.
    Chen CC; Tung SY; Wei KL; Shen CH; Chang TS; Chen WM; Xu HW; Yen CW; Chen YH; Lu SN; Hung CH
    J Formos Med Assoc; 2020 Jan; 119(1 Pt 3):532-537. PubMed ID: 31445848
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sofosbuvir plus ribavirin for the treatment of hepatitis C virus genotype 2 in Korea: What's the optimal dosage of ribavirin in real-world setting?
    Yoon JH; Jun CH; Seo JH; Cho HA; Cho SB; Choi SK; Cho JY; Kim MW; Lim SW
    J Dig Dis; 2019 Jan; 20(1):31-37. PubMed ID: 30548199
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of sofosbuvir plus ribavirin for Korean patients with hepatitis C virus genotype 2 infection: A retrospective multi-institutional study.
    Kim YM; Kim SB; Song IH; Lee SH; Kim HS; Lee TH; Kang YW; Kim SH; Lee BS; Chae HB; Song MJ; Jang JW; Ko SY; Lee JD
    Clin Mol Hepatol; 2018 Sep; 24(3):311-318. PubMed ID: 29865774
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness and safety of community-based treatment with sofosbuvir plus ribavirin for elderly patients with genotype 2 chronic hepatitis C.
    Atsukawa M; Tsubota A; Kondo C; Shimada N; Abe H; Kato K; Okubo T; Arai T; Itokawa N; Iio E; Tanaka Y; Iwakiri K
    Dig Liver Dis; 2017 Sep; 49(9):1029-1035. PubMed ID: 28499694
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness and safety of sofosbuvir plus ribavirin for HCV genotype 2 patients 65 and over with or without cirrhosis.
    Ogawa E; Furusyo N; Nomura H; Takahashi K; Higashi N; Kawano A; Dohmen K; Satoh T; Azuma K; Nakamuta M; Koyanagi T; Kato M; Shimoda S; Kajiwara E; Hayashi J;
    Antiviral Res; 2016 Dec; 136():37-44. PubMed ID: 27789224
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of Sofosbuvir Plus Ribavirin in Veterans With Hepatitis C Virus Genotype 2 Infection, Compensated Cirrhosis, and Multiple Comorbidities.
    Ho SB; Monto A; Peyton A; Kaplan DE; Byrne S; Moon S; Copans A; Rossaro L; Roy A; Le H; Dvory-Sobol H; Zhu Y; Brainard DM; Guyer W; Shaikh O; Fuchs M; Morgan TR;
    Clin Gastroenterol Hepatol; 2017 Feb; 15(2):282-288. PubMed ID: 27237429
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ITPA polymorphism effects on decrease of hemoglobin during sofosbuvir and ribavirin combination treatment for chronic hepatitis C.
    Morio K; Imamura M; Kawakami Y; Nakahara T; Nagaoki Y; Kawaoka T; Tsuge M; Hiramatsu A; Aikata H; Hayes CN; Makokha GN; Ochi H; Amano H; Arataki K; Moriya T; Ito H; Tsuji K; Kohno H; Waki K; Tamura T; Nakamura T; Chayama K;
    J Gastroenterol; 2017 Jun; 52(6):746-753. PubMed ID: 27822709
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and Effectiveness of Ledipasvir and Sofosbuvir, With or Without Ribavirin, in Treatment-Experienced Patients With Genotype 1 Hepatitis C Virus Infection and Cirrhosis.
    Lim JK; Liapakis AM; Shiffman ML; Lok AS; Zeuzem S; Terrault NA; Park JS; Landis CS; Hassan M; Gallant J; Kuo A; Pockros PJ; Vainorius M; Akushevich L; Michael L; Fried MW; Nelson DR; Ben-Ari Z;
    Clin Gastroenterol Hepatol; 2018 Nov; 16(11):1811-1819.e4. PubMed ID: 29306043
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of Sofosbuvir Plus Ribavirin Treatment with Pegylated Interferon Plus Ribavirin Treatment for Chronic Hepatitis C Genotype 2.
    Seo K; Kim SK; Kim SR; Ohtani A; Kobayashi M; Kato A; Morimoto E; Saijo Y; Kim KI; Imoto S; Kim CW; Yano Y; Kudo M; Hayashi Y
    Dig Dis; 2017; 35(6):541-547. PubMed ID: 29040986
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness of Ledipasvir-Sofosbuvir Combination in Patients With Hepatitis C Virus Infection and Factors Associated With Sustained Virologic Response.
    Terrault NA; Zeuzem S; Di Bisceglie AM; Lim JK; Pockros PJ; Frazier LM; Kuo A; Lok AS; Shiffman ML; Ben Ari Z; Akushevich L; Vainorius M; Sulkowski MS; Fried MW; Nelson DR;
    Gastroenterology; 2016 Dec; 151(6):1131-1140.e5. PubMed ID: 27565882
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and Safety of Ledipasvir/Sofosbuvir With and Without Ribavirin in Patients With Chronic HCV Genotype 1 Infection Receiving Opioid Substitution Therapy: Analysis of Phase 3 ION Trials.
    Grebely J; Mauss S; Brown A; Bronowicki JP; Puoti M; Wyles D; Natha M; Zhu Y; Yang J; Kreter B; Brainard DM; Yun C; Carr V; Dore GJ
    Clin Infect Dis; 2016 Dec; 63(11):1405-1411. PubMed ID: 27553375
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anemia associated with antiviral therapy in chronic hepatitis C: incidence, risk factors, and impact on treatment response.
    Hung CH; Lee CM; Lu SN; Wang JH; Chen CH; Hu TH; Kee KM; Chang KC; Tseng PL; Yen YH; Changchien CS
    Liver Int; 2006 Nov; 26(9):1079-86. PubMed ID: 17032408
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness and safety of sofosbuvir plus ribavirin for the treatment of HCV genotype 2 infection: results of the real-world, clinical practice HCV-TARGET study.
    Welzel TM; Nelson DR; Morelli G; Di Bisceglie A; Reddy RK; Kuo A; Lim JK; Darling J; Pockros P; Galati JS; Frazier LM; Alqahtani S; Sulkowski MS; Vainorius M; Akushevich L; Fried MW; Zeuzem S;
    Gut; 2017 Oct; 66(10):1844-1852. PubMed ID: 27418632
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [A phase II, single-arm, open-label, multicenter clinical study to evaluate the efficacy and safety of sofosbuvir combined with ribavirin in patients with genotype 2 chronic hepatitis C virus infection].
    Gao YH; Li GM; Jin QL; Zhao YR; Jia ZS; Mao XR; Yang YF; Shang J; Wang GC; Xie W; Wu SM; Zhang MX; Hou JL; Li DL; Nan YM; Guan YJ; Zhu CX; Yuan YZ; Wei L
    Zhonghua Gan Zang Bing Za Zhi; 2019 May; 27(5):352-357. PubMed ID: 31177659
    [No Abstract]   [Full Text] [Related]  

  • 15. Real-World Experiences With a Direct-Acting Antiviral Agent for Patients With Hepatitis C Virus Infection.
    Louie V; Latt NL; Gharibian D; Sahota A; Yanny BT; Mittal R; Bider-Canfield Z; Cheetham TC
    Perm J; 2017; 21():16-096. PubMed ID: 28368787
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correlation between polymorphism in the inosine triphosphatase and the reductions in hemoglobin concentration and ribavirin dose during sofosbuvir and ribavirin therapy.
    Kozuka R; Hai H; Teranishi Y; Motoyama H; Kawamura E; Hagihara A; Uchida-Kobayashi S; Morikawa H; Enomoto M; Murakami Y; Kawada N; Tamori A
    J Gastroenterol Hepatol; 2017 Aug; 32(8):1495-1502. PubMed ID: 28109022
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sofosbuvir-based direct acting antiviral therapies for patients with hepatitis C virus genotype 2 infection.
    Liu CH; Su TH; Liu CJ; Hong CM; Yang HC; Tseng TC; Chen PJ; Chen DS; Kao JH
    J Gastroenterol Hepatol; 2019 Sep; 34(9):1620-1625. PubMed ID: 30693965
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sofosbuvir-based therapy for patients with chronic hepatitis C: Early experience of its efficacy and safety in Korea.
    Cho Y; Cho EJ; Lee JH; Yu SJ; Yoon JH; Kim YJ
    Clin Mol Hepatol; 2015 Dec; 21(4):358-64. PubMed ID: 26770924
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sofosbuvir Plus Velpatasvir Combination Therapy for Treatment-Experienced Patients With Genotype 1 or 3 Hepatitis C Virus Infection: A Randomized Trial.
    Pianko S; Flamm SL; Shiffman ML; Kumar S; Strasser SI; Dore GJ; McNally J; Brainard DM; Han L; Doehle B; Mogalian E; McHutchison JG; Rabinovitz M; Towner WJ; Gane EJ; Stedman CA; Reddy KR; Roberts SK
    Ann Intern Med; 2015 Dec; 163(11):809-17. PubMed ID: 26551263
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of Sofosbuvir and Velpatasvir, With and Without Ribavirin, in Patients With Hepatitis C Virus Genotype 3 Infection and Cirrhosis.
    Esteban R; Pineda JA; Calleja JL; Casado M; Rodríguez M; Turnes J; Morano Amado LE; Morillas RM; Forns X; Pascasio Acevedo JM; Andrade RJ; Rivero A; Carrión JA; Lens S; Riveiro-Barciela M; McNabb B; Zhang G; Camus G; Stamm LM; Brainard DM; Subramanian GM; Buti M
    Gastroenterology; 2018 Oct; 155(4):1120-1127.e4. PubMed ID: 29958855
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.